Global Custom Market Research Reports Provider Company

phone

Tourette Syndrome - Pipeline Review, H2 2018

  • Published Date: 10 Jul 2018
  • Number of Pages: 79
  • Category: Pharmaceuticals
  • Country: Global
Tourette Syndrome - Pipeline Review, H2 2018

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Tourette Syndrome - Pipeline Review, H2 2018, provides an overview of the Tourette Syndrome (Central Nervous System) pipeline landscape.

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Tourette Syndrome - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Tourette Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tourette Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 5, 2, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Tourette Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Tourette Syndrome - Overview
Tourette Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tourette Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tourette Syndrome - Companies Involved in Therapeutics Development
Abide Therapeutics Inc
Catalyst Pharmaceuticals Inc
Neurocrine Biosciences Inc
Psyadon Pharmaceuticals Inc
SOM Biotech SL
Teva Pharmaceutical Industries Ltd
Therapix Biosciences Ltd
Zynerba Pharmaceuticals Inc
Tourette Syndrome - Drug Profiles
(amfetamine + guanfacine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABX-1431 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bevantolol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPP-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
deutetrabenazine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ecopipam hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize DRD2 for CNS Disorders and Hormonal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THX-110 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THX-120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
valbenazine tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vigabatrin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZYN-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tourette Syndrome - Dormant Projects
Tourette Syndrome - Discontinued Products
Tourette Syndrome - Product Development Milestones
Featured News & Press Releases
Jun 11, 2018: Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome
Apr 10, 2018: Abide Therapeutics Presents Positive Data from a Phase 1b Study of ABX-1431 in Tourette Syndrome at the American Academy of Neurology 70th Annual Meeting
Apr 09, 2018: Therapix Biosciences Announces Top line Results of Phase IIa Study at Yale University for Tourette Syndrome Program
Feb 28, 2018: Nuvelution Pharma Announces Commencement of Patient Enrollment in Phase II/III Clinical Study of AUSTEDO (deutetrabenazine) for the Treatment of Tourette syndrome in Pediatric Patients
Feb 07, 2018: Abide Therapeutics to Participate in February 2018 Investor Conferences
Feb 07, 2018: Therapix Biosciences Completes Pre-IND Communication With FDA on THX-110 for Tourette Syndrome: Clinical Development to Proceed as Projected
Jan 03, 2018: Zynerba Pharmaceuticals Provides Update on fibromyalgia Drug Candidate ZYN-001
Dec 04, 2017: Therapix Biosciences Announces Completion of Enrollment of Phase IIa Study at Yale University for Tourette Syndrome Program
Nov 28, 2017: Abide Therapeutics Reports Positive Top line Data from Phase 1b Study of ABX-1431 in Tourette Syndrome
Oct 25, 2017: Neurocrine Initiates Phase IIb Clinical Study of Once-daily INGREZZA in Children and Adolescents with Tourette Syndrome
Oct 23, 2017: Neurocrine Granted FDA Orphan Drug Designation for Valbenazine for the Treatment of Pediatric Patients With Tourette Syndrome
Oct 11, 2017: Nippon Chemiphar and SOM Biotech to Cooperate on New, Orphan Disease Indications for Bevantolol (Calvan)
May 23, 2017: Neurocrine Announces Phase II Results of VMAT2 Inhibitor INGREZZA For Treatment of Tourette Syndrome
May 08, 2017: Therapix Biosciences and the Hannover Medical School Enter into an Investigator-initiated Clinical Trial Agreement to Assess the Effect of TXH-TS01 in Patients with Tourette Syndrome
Apr 18, 2017: Abide Therapeutics Announces Dosing of First Patient In Phase 1b Study of ABX-1431 in Tourette Syndrome and Collaboration with Tourette Association of America
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

List of Tables
Number of Products under Development for Tourette Syndrome, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Tourette Syndrome - Pipeline by Abide Therapeutics Inc, H2 2018
Tourette Syndrome - Pipeline by Catalyst Pharmaceuticals Inc, H2 2018
Tourette Syndrome - Pipeline by Neurocrine Biosciences Inc, H2 2018
Tourette Syndrome - Pipeline by Psyadon Pharmaceuticals Inc, H2 2018
Tourette Syndrome - Pipeline by SOM Biotech SL, H2 2018
Tourette Syndrome - Pipeline by Teva Pharmaceutical Industries Ltd, H2 2018
Tourette Syndrome - Pipeline by Therapix Biosciences Ltd, H2 2018
Tourette Syndrome - Pipeline by Zynerba Pharmaceuticals Inc, H2 2018
Tourette Syndrome - Dormant Projects, H2 2018
Tourette Syndrome - Discontinued Products, H2 2018

List Of Figures

List of Figures
Number of Products under Development for Tourette Syndrome, H2 2018 8
Number of Products under Development by Companies, H2 2018 9
Number of Products by Top 10 Targets, H2 2018 13
Number of Products by Stage and Top 10 Targets, H2 2018 13
Number of Products by Top 10 Mechanism of Actions, H2 2018 15
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018 15
Number of Products by Routes of Administration, H2 2018 17
Number of Products by Stage and Routes of Administration, H2 2018 17
Number of Products by Stage and Top 10 Molecule Types, H2 2018 19

Transmembrane Prolyl 4 Hydroxylase (Hypoxia Inducible Factor Prolyl Hydroxylase 4 or P4HTM or EC 1.14.11.) - Pipeline Review, H2 2018 According to the recently published report Transmembrane Prolyl 4 Hydroxylase -

View Report

CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) - Pipeline Review, H2 2018 CD40 Ligand (T

View Report

Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1 Associated Factor 1 or HDAC2 or EC 3.5.1.98) - Pipeline Review, H2 2018 Histone Deacetylase 2 (Transcriptional Regulator Homolog RPD3 or YY1

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports